BIVF at al. lead €20m series-A for ImCheck Therapeutics

Kurma Partners, Idinvest, Gimv and Life Sciences Partners (LSP) also took part in the funding round. According to a statement, Gimv provided a €5m equity ticket as part of the funding round.

Furthermore, the company hired sector professional Pierre d'Epenoux as CEO, while Rémi Droller, managing partner at Kurma, became chairperson. The company's board was completed with BIVF's Detlev Mennerich, Gimv's Karl Nägler and LSP's Vincent Brichard.

Following the transaction, the company aims to use the fresh capital to improve the response and clinical outcome of its proprietary immunotherapy approaches and plans to enter clinical trials by 2019.

Company
ImCheck develops immunomodulatory antibodies acting on both adaptive and innate immunity, focusing on cancer and auto-immunity disease therapies. The pre-revenues business span out from Marseille's Institut Paoli-Calmettes in 2015.

People
Gimv – Karl Nägler (partner).
Kurma Partners – Rémi Droller (managing partner).
Boehringer Ingelheim Venture Fund – Detlev Mennerich (director).
Life Sciences Partners – Vincent Brichard (partner).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• Healthcare
• France
• Venture
• France
• Gimv
• Life Science Partners